Centene (CNC) Stock Price, News & Analysis

Company Overview

Centene Corporation operates as a healthcare enterprise that provides programs and services to under-insured and uninsured families, commercial organizations, and military families in the United States. The company operates through Medicaid, Medicare, Commercial, and Other segments. The Medicaid segment offers health plan coverage, including medicaid expansion, aged, blind, disabled, children's health insurance program, foster care, medicare-medicaid plans, long-term services and support. This segment also provides healthcare products. The Medicare segment offers special needs and medicare supplement, and prescription drug plans. The Commercial segment provides health insurance marketplace product for individual, small, and large group commercials. It also operates clinical healthcare and pharmacies, as well as offers dental and speech therapy services. In addition, the company engages in the government contracts business under the TRICARE program and other healthcare related government contracts. It provides services through primary and specialty care physicians, hospitals, and ancillary providers. Centene Corporation was founded in 1984 and is headquartered in Saint Louis, Missouri.

Key Stats

• Today's Range: $61.95 to $63.94
• 50-Day Range: $55.94 to $64.37
• 52-Week Range: $55.03 to $80.59
• Volume: 3.89 million shs
• Average Volume: 4.69 million shs
• Market Capitalization: $31.66 billion
• P/E Ratio: 10.23
• Dividend Yield: N/A
• Price Target: $80.85
• Consensus Rating: Moderate Buy

Centene Stock Analysis - MarketRank™

Centene scored higher than 97% of companies evaluated by MarketBeat, and ranked 20th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Centene has received a consensus rating of Moderate Buy. The company's average rating score is 2.56, and is based on 9 buy ratings, 7 hold ratings, and no sell ratings.

Amount of Analyst Coverage

Centene has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 3.8 / 5
• Proj. Earnings Growth: 7.43%

Earnings Growth

Earnings for Centene are expected to grow by 7.43% in the coming year, from $6.86 to $7.37 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Centene is 10.23, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 21.04.

Price to Earnings Ratio vs. Sector

The P/E ratio of Centene is 10.23, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 21.36.

Price to Earnings Growth Ratio

Centene has a PEG Ratio of 0.80. PEG Ratios below 1 indicate that a company could be undervalued.

Price to Book Value per Share Ratio

Centene has a P/B Ratio of 1.19. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.46% of the float of Centene has been sold short.

Short Interest Ratio / Days to Cover

Centene has a short interest ratio ("days to cover") of 1.5, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Centene has recently decreased by 27.95%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Centene does not currently pay a dividend.

Dividend Growth

Centene does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 3.6 / 5
• Environmental Score: -0.41

Percentage of Shares Shorted

1.46% of the float of Centene has been sold short.

Short Interest Ratio / Days to Cover

Centene has a short interest ratio ("days to cover") of 1.5, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Centene has recently decreased by 27.95%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 3.4 / 5
• News Sentiment: 1.18

News Sentiment

Centene has a news sentiment score of 1.18. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.95 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 41 news articles for Centene this week, compared to 17 articles on an average week.

Search Interest

Only 12 people have searched for CNC on MarketBeat in the last 30 days. This is a decrease of -20% compared to the previous 30 days.

MarketBeat Follows

10 people have added Centene to their MarketBeat watchlist in the last 30 days. This is an increase of 67% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Centene insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 0.33% of the stock of Centene is held by insiders.

Percentage Held by Institutions

93.63% of the stock of Centene is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

CNC Stock Analysis - Frequently Asked Questions

How have CNC shares performed this year?

Centene's stock was trading at $60.58 on January 1st, 2025. Since then, CNC shares have increased by 5.3% and is now trading at $63.82.
View the best growth stocks for 2025 here.

How were Centene's earnings last quarter?

Centene Co. (NYSE:CNC) issued its quarterly earnings results on Tuesday, February, 4th. The company reported $0.80 EPS for the quarter, beating analysts' consensus estimates of $0.49 by $0.31. The business's quarterly revenue was up 3.4% on a year-over-year basis.
Read the conference call transcript.

When did Centene's stock split?

Centene's stock split on the morning of Wednesday, February 6th 2019. The 2-1 split was announced on Tuesday, February 5th 2019. The newly minted shares were payable to shareholders after the closing bell on Tuesday, February 5th 2019. An investor that had 100 shares of stock prior to the split would have 200 shares after the split.

Does Centene have any subsidiaries?

Centene subsidiaries include these companies: Magellan Health Inc, PANTHERx Rare Pharmacy, Apixio, WellCare Health Plans, Community Medical Group, MHM, Fidelis Care, and more.

Who are Centene's major shareholders?

Centene's top institutional investors include Rhumbline Advisers (0.23%), GAMMA Investing LLC (0.07%), QV Investors Inc. (0.05%) and Czech National Bank (0.02%). Insiders that own company stock include Sarah London, Andrew Lynn Asher, Kenneth J Fasola, Shannon Bagley, Christopher J Coughlin, Theodore R Samuels II, Richard A Gephardt, Thomas Greco, Lori Jean Robinson and H James Dallas.
View institutional ownership trends.

How do I buy shares of Centene?

Shares of CNC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Centene own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Centene investors own include Humana (HUM), NVIDIA (NVDA), Meta Platforms (META), American Water Works (AWK), Salesforce (CRM), Advanced Micro Devices (AMD) and Verizon Communications (VZ).

Company Calendar

• Last Earnings: 2/04/2025
• Today: 4/13/2025
• Next Earnings (Estimated): 4/25/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Medical
• Industry: Hospital & medical service plans
• Sub-Industry: Managed Health Care
• Current Symbol: NYSE:CNC
• CIK: 1071739
• Web: www.centene.com
• Phone: (314) 725-4477
• Fax: 314-558-2428
• Employees: 74,300
• Year Founded: 1984

Price Target and Rating

• Average Stock Price Target: $80.85
• High Stock Price Target: $93.00
• Low Stock Price Target: $64.00
• Potential Upside/Downside: +26.7%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.56
• Research Coverage: 16 Analysts

Profitability

• EPS (Most Recent Fiscal Year): $6.24
• Trailing P/E Ratio: 10.23
• Forward P/E Ratio: 9.30
• P/E Growth: 0.8
• Net Income: $3.31 billion
• Net Margins: 2.03%
• Pretax Margin: 2.61%
• Return on Equity: 13.85%
• Return on Assets: 4.54%

Debt

• Debt-to-Equity Ratio: 0.70
• Current Ratio: 1.11
• Quick Ratio: 1.10

Sales & Book Value

• Annual Sales: $163.07 billion
• Price / Sales: 0.19
• Cash Flow: $10.80 per share
• Price / Cash Flow: 5.91
• Book Value: $53.42 per share
• Price / Book: 1.19

Miscellaneous

• Outstanding Shares: 496,060,000
• Free Float: 494,407,000
• Market Cap: $31.66 billion
• Optionable: Optionable
• Beta: 0.53